TriangleNCT02749227 · STUDY IN CONTEXT
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-pituitary-tumors
- nct id
- NCT02749227
- trial label
- Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 2
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-pituitary-tumors
- nct id
- NCT02749227
- outcome key
- om-0000
- source section id
- NCT02749227-om-0000
- source outcome index
- 0
- endpoint
- Change in Plasma Proopiomelanocortin (POMC) Levels
- endpoint definition
- This is to measure the effect of Pasireotide LAR (long-acting release) treatment.
- time origin
- Baseline, 12 months
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- The study was terminated due to poor enrollment. The data was not collected or analyzed.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-pituitary-tumors
- nct id
- NCT02749227
- outcome key
- om-0001
- source section id
- NCT02749227-om-0001
- source outcome index
- 1
- endpoint
- Change in Pituitary Tumor Volume
- endpoint definition
- This is to measure the effect of Pasireotide LAR (long-acting release) treatment.
- time origin
- Baseline, 12 months
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- The study was terminated due to poor enrollment. The data was not collected or analyzed.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-pituitary-tumors
- nct id
- NCT02749227
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Pasireotide LAR Therapy
- regimen
- Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed. Pasireotide LAR: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use. The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.
- analyzed count
- 0
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02749227-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-pituitary-tumors
- nct id
- NCT02749227
- outcome key
- om-0001
- arm key
- OG000
- arm label
- Pasireotide LAR Therapy
- regimen
- Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed. Pasireotide LAR: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use. The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.
- analyzed count
- 0
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02749227-om-0001#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-pituitary-tumors
- nct id
- NCT02749227
- harm key
- EG000
- source section id
- NCT02749227-ae
- event group key
- EG000
- event group label
- Pasireotide LAR Therapy
- serious affected
- 0
- serious at risk
- 4
- other affected
- 0
- other at risk
- 4
- frequency threshold
- 5
- collection period
- Up to 12 months
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice